Across
- 1. An engineering descriptor for targeted biologic agents designed to bind to a single specific epitope or signaling molecule.
- 7. A highly sulfated glycosaminoglycan anticoagulant that activates antithrombin three to rapidly inhibit thrombin and factor ten-a.
- 10. A purine analogue prodrug that converts to six-mercaptopurine, disrupting nucleic acid synthesis in highly active immune cells.
- 12. A specialized monoclonal antibody that binds to the complement protein C5, blocking terminal complement activation in paroxysmal hemoglobinuria.
- 13. A chimeric monoclonal antibody against TNF-alpha administered via intravenous infusion, requiring screening for latent tuberculosis.
- 18. An antineoplastic agent that increases the production of fetal hemoglobin, widely utilized to minimize painful crises in sickle cell disease.
- 22. The immature erythrocyte monitored closely during epoetin alfa therapy to evaluate the speed of bone marrow erythropoiesis.
- 23. A low-molecular-weight heparin administered subcutaneously that preferentially accelerates the inactivation of clotting factor ten-a.
- 24. A direct oral anticoagulant that selectively inhibits factor ten-a, requiring no routine laboratory coagulation monitoring.
- 26. A chimeric monoclonal antibody that binds explicitly to the CD20 antigen on B cells, inducing rapid depletion of malignant or auto-reactive lines.
- 27. The critical primary hemostasis process that is targeted and blocked by antiplatelet drugs like aspirin and clopidogrel.
- 28. The precise pharmacological balance required when monitoring anticoagulant therapy to prevent systemic thrombosis while avoiding active hemorrhage.
- 29. The cross-linked protein polymer targeted for dissolution by thrombolytic tissue plasminogen activator variants during stroke protocols.
- 30. An antimetabolite antifolate drug utilized at low doses for immunosuppression in autoimmune conditions, carrying risks of hepatotoxicity.
Down
- 2. The chemical cascade step that turns liquid blood into a solid gel, heavily targeted by anticoagulant medications.
- 3. The primary, universal adverse effect that must be stringently evaluated during all anticoagulant and antiplatelet drug regimens.
- 4. A potent macrolide calcineurin inhibitor used to prevent solid organ transplant rejection, carrying a high risk of new-onset post-transplant diabetes.
- 5. Soluble cellular target factors used to isolate or profile specific monoclonal antibody responses during diagnostic drug design.
- 6. A direct oral anticoagulant (DOAC) that acts as a reversible thrombin inhibitor, requiring specific reversal with idarucizumab in emergencies.
- 8. A fully human monoclonal antibody that binds directly to tumor necrosis factor-alpha, utilized to manage severe rheumatoid arthritis and Crohn's.
- 9. A highly basic protein administered intravenously to rapidly reverse the anticoagulant actions of unfractionated heparin via ionic binding.
- 11. A recombinant tissue plasminogen activator (tPA) that converts trapped plasminogen to active plasmin, utilized as an emergency clot-buster.
- 14. A calcineurin inhibitor immunosuppressant that blocks interleukin-two transcription, carrying prominent risks of nephrotoxicity and gingival hyperplasia.
- 15. An immunosuppressant that inhibits inosine monophosphate dehydrogenase, selectively blocking de novo purine synthesis in proliferating T and B lymphocytes.
- 16. A classic oral vitamin K antagonist that blocks the gamma-carboxylation of clotting factors two, seven, nine, and ten, monitored via INR.
- 17. A recombinant granulocyte colony-stimulating factor (G-CSF) administered to stimulate bone marrow neutrophil production in severe neutropenia.
- 19. An antifibrinolytic drug formerly utilized to decrease blood loss during complex cardiac surgery by inhibiting systemic plasmin cascades.
- 20. The coagulation pathway monitored clinically using the activated partial thromboplastin time (aPTT), prolonged by intravenous heparin.
- 21. An antiplatelet prodrug that irreversibly blocks the P2Y12 adenosine diphosphate receptor on platelet membranes to prevent aggregation.
- 25. The functional receptor or enzyme classification for drugs like warfarin, dabigtran, and clopidogrel that work by blocking steps.